Jambolan - Liraglutide Recombinant Interaction

Interaction Details

Liraglutide Recombinant is classified as belonging to the following category: Antidiabetes Drugs

Animal research shows that jambolan seed and bark extracts can lower blood glucose levels. Theoretically, jambolan might have additive effects when used with antidiabetes drugs. This might increase the risk of hypoglycemia in some patients. Monitor blood glucose levels closely.

Interaction Rating

Likelihood of Occurrence

Interaction has been documented in animal or in lab research, or the interaction has been documented in humans but is limited to case reports or conflicting clinical research exists

References

• Sharma SB, Nasir A, Prabhu KM, et al. Hypoglycaemic and hypolipidemic effect of ethanolic extract of seeds of Eugenia jambolana in alloxan-induced diabetic rabbits. J Ethnopharmacol 2003;85:201-6.
• Sridhar SB, Sheetal UD, Pai MR, Shastri MS. Preclinical evaluation of the antidiabetic effect of Eugenia jambolana seed powder in streptozotocin-diabetic rats. Braz J Med Biol Res 2005;38:463-8.
• Villasenor IM, Lamadrid MR. Comparative anti-hyperglycemic potentials of medicinal plants. J Ethnopharmacol 2006;104:129-31.
• Vora A, Varghese A, Kachwala Y, et al. Eugenia jambolana extract reduces the systemic exposure of Sitagliptin and improves conditions associated with diabetes: A pharmacokinetic and a pharmacodynamic herb-drug interaction study. J Tradit Complement Med. 2

Liraglutide Recombinant Overview

• Liraglutide injection (Victoza) is used with a diet and exercise program to control blood sugar levels in adults and children 10 years of age and older with type 2 diabetes (condition in which the body does not use insulin normally and therefore cannot control the amount of sugar in the blood) when other medications did not control levels well enough. Liraglutide injection (Victoza) is also used to reduce the risk of a heart attack, stroke, or death in adults with type 2 diabetes mellitus and heart and blood vessel disease. Liraglutide injection (Victoza) is not used to treat type 1 diabetes (condition in which the body does not produce insulin and therefore cannot control the amount of sugar in the blood) or diabetic ketoacidosis (a serious condition that may develop if high blood sugar is not treated) in adults. Liraglutide injection (Saxenda) is used along with a reduced calorie diet and exercise plan to help certain adults and children 12 years of age and older who weigh 132 pounds (60 kg) or more and who are obese or who are overweight and have weight-related medical problems to lose weight and to keep from gaining back that weight. Liraglutide injection (Saxenda) is not used to treat type 2 diabetes. Liraglutide injection is in a class of medications called incretin mimetics. It works by helping the pancreas to release the right amount of insulin when blood sugar levels are high. Insulin helps move sugar from the blood into other body tissues where it is used for energy. Liraglutide injection also slows the emptying of the stomach and may decrease appetite and cause weight loss.

• Over time, people who have diabetes and high blood sugar can develop serious or life-threatening complications, including heart disease, stroke, kidney problems, nerve damage, and eye problems. Using medication(s), making lifestyle changes (e.g., diet, exercise, quitting smoking), and regularly checking your blood sugar may help to manage your diabetes and improve your health. This therapy may also decrease your chances of having a heart attack, stroke, or other diabetes-related complications such as kidney failure, nerve damage (numb, cold legs or feet; decreased sexual ability in men and women), eye problems, including changes or loss of vision, or gum disease. Your doctor and other healthcare providers will talk to you about the best way to manage your diabetes.

Jambolan - More Interactions

Jambolan interacts with 182 drugs

Interaction Rating Key

These severity listings are for informational use only. Never start, stop or otherwise change your therapy before speaking with your provider.